This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
by Zacks Equity Research
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
NVOPositive Net Change LLYNegative Net Change CPRXNegative Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
by Zacks Equity Research
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
BIIBNegative Net Change CPRXNegative Net Change ADMAPositive Net Change APLSPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
by Zacks Equity Research
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
BIIBNegative Net Change LLYNegative Net Change GILDNegative Net Change CNTANegative Net Change
biotechs medical pharmaceuticals
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
by Zacks Equity Research
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
by Sundeep Ganoria
ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?
REGNNegative Net Change ABBVNegative Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
by Sundeep Ganoria
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
REGNNegative Net Change ABBVNegative Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease
by Sundeep Ganoria
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
REGNNegative Net Change ABBVNegative Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
by Zacks Equity Research
RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26.
CPRXNegative Net Change ANIPNegative Net Change RAREPositive Net Change INDVNegative Net Change
biotechs
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso Study
by Zacks Equity Research
United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA filing.
UTHRNegative Net Change CPRXNegative Net Change ANIPNegative Net Change INDVNegative Net Change
biotechs
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
NVSNegative Net Change BIIBNegative Net Change RHHBYNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals